On 9 March 2015 the UK Competition and Markets Authority (“CMA”) unconditionally cleared the acquisition by Perrigo of Omega after a Phase I investigation. The transaction combined Perrigo, which contract manufactures OTC pharmaceutical products for other pharmaceutical companies and, in particular, private label products for retailers and pharmacy chains, and Omega, which supplied branded OTC pharmaceuticals. The CMA focused on potential concerns arising from the overlap between the Parties in the supply of OTC sleeping aids. RBB provided an in-depth assessment demonstrating the absence of an incentive for each party to increase price post-merger. RBB worked alongside Freshfields Bruckhaus Deringer, legal advisers to Perrigo.
Our experience and expertise means our clients have the best chance of success before competition authorities and courts.
We have unrivalled experience across the full range of issues presented by competition law and related associated litigation.
